Circio and GenAssist Collaborate on Gene Therapy for Muscle Disease and In Vivo Cell Therapy

▤ Summary

Circio and GenAssist have formed a research collaboration to develop circVec-enhanced AAV vectors for in vivo cell therapy and low-dose systemic gene therapy. The partnership targets genetic muscle disease, where current approaches often require high doses that can cause toxicity. The companies will also explore joint in vivo CAR T candidates for oncology and autoimmune uses. They will test the combined AAV constructs in vitro and in vivo before nominating successful candidates for preclinical development.

▦ Linked Companies